Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| RO06309 | Other Identifier | UW Carbone Cancer Center | |
| A533300 | Other Identifier | UW Madison | |
| SMPH\HUMAN ONCOLOGY\HUMAN ONCO | Other Identifier | UW Madison |
Not provided
Not provided
Not provided
Not provided
change in imaging priorities
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Hypoxia is a key factor in malignant progression of a neoplasm. It is our aim to explore the basis for quantitative in vivo tumor imaging by Cu-61 diacetyl-bis(N4-methylthiosemicarbazone)PET imaging as a surrogate of tissue hypoxia. We hypothesize that the hypoxia levels are predictive of the tumor response to therapy. Patients will have 2 CU-ATSM PET scans done and the goal is to show spatially stable tracer distributions that correlate with tumor hypoxia. This study will serve as a pilot study for a PO1 submission
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 CNS | Experimental | imaging with CuATSM |
|
| 2. Head and Neck | Experimental | Imaging with CuATSM |
|
| 3. Lung | Experimental | imaging with CuATSM |
|
| 4. Prostate | Experimental | PET imaging with CuATSM |
|
| 5. Esophagus | Experimental | PET imaging with CuATSM |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PET-imaging with CuATSM | Procedure | imaging with CuATSM |
| |
| PET Imaging |
| Measure | Description | Time Frame |
|---|---|---|
| To validate the CuATSM-PET imaging by correlation to the serum level of osteopontin, a marker of hypoxia | end of study |
| Measure | Description | Time Frame |
|---|---|---|
| To test reliability of the CuATSM uptake by quantifying the reproducibility of the pre-treatment CuATSM_PET scans | end of study | |
| To assess the technical and logistic feasibility of CuATSM-PET scans in a population of cancer patients | end of study |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Robert Jeraj, Ph.D | University of Wisconsin, Madison | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Wisconsin Hospital and Clinics | Madison | Wisconsin | 53792 | United States |
Not provided
| ID | Term |
|---|---|
| D006258 | Head and Neck Neoplasms |
| D008175 | Lung Neoplasms |
| D011471 | Prostatic Neoplasms |
| D004938 | Esophageal Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D012142 | Respiratory Tract Neoplasms |
| D013899 | Thoracic Neoplasms |
Not provided
Not provided
| ID | Term |
|---|---|
| D009682 | Magnetic Resonance Spectroscopy |
| C000720849 | CuATSM |
| ID | Term |
|---|---|
| D013057 | Spectrum Analysis |
| D002623 | Chemistry Techniques, Analytical |
| D008919 | Investigative Techniques |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Procedure |
Imaging with CuATSM |
|
| PET CuATSM | Procedure | Imaging with CuATSM |
|
| PET imaging | Procedure | imaging with CuATSM |
|
| PET imaging with CuATSM | Procedure | Imaging with CuATSM |
|
| PET imaging with CuATSM | Procedure | Imaging with CuATSM |
|
| D008171 |
| Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D005832 | Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D011469 | Prostatic Diseases |
| D052801 | Male Urogenital Diseases |
| D005770 | Gastrointestinal Neoplasms |
| D004067 | Digestive System Neoplasms |
| D004066 | Digestive System Diseases |
| D004935 | Esophageal Diseases |
| D005767 | Gastrointestinal Diseases |